- Home
- SOPH
SOPH
SOPHiA GENETICS SA
as of 11-02-2026 3:37pm EST
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 462.3M | IPO Year: | 2021 |
| Target Price: | $9.75 | AVG Volume (30 days): | 535.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $3.83 - $8.98 | Next Earning Date: | 11-03-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 23.24% | Revenue Growth (next year): | 24.63% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)
Executive Chairman
Avg Cost/Share
$7.26
Shares
8,500
Total Value
$61,670.90
Owned After
3,387,150
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$7.26
Shares
5,000
Total Value
$36,303.00
Owned After
195,993
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$8.12
Shares
6,168
Total Value
$50,100.20
Owned After
332,716
SEC Form 4
Executive Chairman
Avg Cost/Share
$8.13
Shares
40,172
Total Value
$326,526.05
Owned After
3,387,150
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$8.13
Shares
7,394
Total Value
$60,099.91
Owned After
195,993
SEC Form 4
Chief People Officer
Avg Cost/Share
$8.13
Shares
4,240
Total Value
$34,487.31
Owned After
206,210
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$8.13
Shares
9,838
Total Value
$79,971.13
Owned After
660,391
SEC Form 4
Chief Sales Officer
Avg Cost/Share
$7.99
Shares
216
Total Value
$1,736.62
Owned After
147,763
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Xu Zhenyu | SOPH | Chief Scientific Officer | Oct 13, 2026 | Sell | $7.18 | 4,000 | $28,727.20 | 541,493 | |
| Camblong Jurgi | SOPH | Executive Chairman | Oct 12, 2026 | Sell | $7.26 | 8,500 | $61,670.90 | 3,387,150 | |
| Menu Philippe | SOPH | Chief Medical Officer | Oct 12, 2026 | Sell | $7.26 | 5,000 | $36,303.00 | 195,993 | |
| Van Well Daan | SOPH | Chief Legal Officer | Oct 5, 2026 | Sell | $8.12 | 6,168 | $50,100.20 | 332,716 | |
| Camblong Jurgi | SOPH | Executive Chairman | Oct 5, 2026 | Sell | $8.13 | 40,172 | $326,526.05 | 3,387,150 | |
| Menu Philippe | SOPH | Chief Medical Officer | Oct 5, 2026 | Sell | $8.13 | 7,394 | $60,099.91 | 195,993 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Oct 5, 2026 | Sell | $8.12 | 7,394 | $60,074.77 | 541,493 | |
| Valente Manuela | SOPH | Chief People Officer | Oct 5, 2026 | Sell | $8.13 | 4,240 | $34,487.31 | 206,210 | |
| Muken Ross | SOPH | Chief Executive Officer | Oct 5, 2026 | Sell | $8.13 | 9,838 | $79,971.13 | 660,391 | |
| Puylaert Kevin | SOPH | Chief Sales Officer | Oct 5, 2026 | Sell | $7.99 | 216 | $1,736.62 | 147,763 |
Compare SOPH vs Leading Stocks
See how SOPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SOPH SOPHiA GENETICS SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.